Acrivastine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Acrivastine
Acrivastine.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa682619
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life1.5 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.110.306 Edit this at Wikidata
Chemical and physical data
FormulaC22H24N2O2
Molar mass348.438 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking histamine H1 receptors.

This non-sedating[verification needed] antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories. It should not be confused with Benadryl Once a Day which has cetirizine as the active ingredient and is also sold by McNeil in the UK. It is available as an over-the-counter medicine in the UK, and is available with or without pseudoephedrine under the Benadryl brand.

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D also contains the decongestant pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

Comparisons with other popular antihistamines[edit]

Unlike cetirizine or loratadine, for which the standard dose is one tablet per day, a single acrivastine tablet may be taken up to three times a day.[2] It is not to be taken by people over the age of 65, pregnant women, or people with compromised liver or kidney function.

References[edit]

  1. ^ SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
  2. ^ "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Archived from the original on 27 September 2012. Retrieved 4 July 2014.